Overview

Safety and Efficacy of Celecoxib Versus Naproxen in the 6-month Treatment of Knee Osteoarthritis

Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
To compare the safety and efficacy of celecoxib versus naproxen for the treatment of knee osteoarthritis
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Celecoxib
Naproxen